Familial membranous nephropathy: an X-linked genetic susceptibility?

Detlef Bockenhauer1, Hanna Debiec, Neil Sebire

  • 1Department of Nephrology, Great Ormond Street Hospital, London, UK. Detlef.Bockenhauer@nhs.net

Nephron. Clinical Practice
|December 14, 2007
PubMed
Abstract

Insights

This study identifies a potential X-linked genetic factor contributing to membranous nephropathy (MN), a common cause of kidney failure. Further research into this genetic predisposition could lead to new treatments for MN.

Area of Science:

  • Nephrology
  • Genetics
  • Immunology

Background:

  • Membranous nephropathy (MN) is a primary cause of nephrotic syndrome in adults and a leading cause of kidney failure.
  • The etiology of MN remains largely unknown, with anti-glomerular antibodies implicated but no specific genetic defects identified.

Purpose of the Study:

  • To investigate a potential X-linked genetic susceptibility to primary membranous nephropathy (MN) within a multigenerational family.
  • To explore the role of anti-glomerular antibodies in the pathogenesis of MN.

Main Methods:

  • Studied a family with four members across three generations affected by primary MN.
  • Assessed serum from affected members and their mothers for anti-glomerular antibodies.

Main Results:

  • Identified a pattern suggestive of X-linked inheritance, with all affected individuals being male and linked through the maternal line.
  • Observed a wide age of onset (1-67 years), indicating genetic predisposition influenced by other factors.
  • Detected antibodies against glomerular and peritubular endothelial cells in the mother of the youngest patient.

Conclusions:

  • Reported the largest family with potential X-linked susceptibility to MN.
  • Suggested foeto-maternal alloimmunization as a potential trigger in the youngest patient.
  • Highlighted the implications of identifying an X-linked factor for understanding sporadic MN and developing treatments.

Related Concept Videos

Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...